Effect and Safety of Hydroxysafflor Yellow A for Injection in Patients with Acute Ischemic Stroke of Blood Stasis Syndrome: A Phase Ⅱ, Multicenter, Randomized, Double-Blind, Multiple-Dose, Active-Controlled Clinical Trial

Ming-zhe HU; Zi-yi ZHOU; Zhong-yu ZHOU; Hui LU; Min GAO; Long-min LIU; Hai-qing SONG; An-ji LIN; Qing-ming WU; Hong-fei ZHOU; Lei LI; Xia WANG; Ye-feng CAI

doi:10.1007/s11655-020-3094-7

Your Location：

Home >

Browse articles >

Effect and Safety of Hydroxysafflor Yellow A for Injection in Patients with Acute Ischemic Stroke of Blood Stasis Syndrome: A Phase Ⅱ, Multicenter, Randomized, Double-Blind, Multiple-Dose, Active-Controlled Clinical Trial

Original Article | Updated：2021-08-23

- Effect and Safety of Hydroxysafflor Yellow A for Injection in Patients with Acute Ischemic Stroke of Blood Stasis Syndrome: A Phase Ⅱ, Multicenter, Randomized, Double-Blind, Multiple-Dose, Active-Controlled Clinical Trial
- Chinese Journal of Integrative Medicine Vol. 26, Issue 6, Pages: 420-427(2020)
- Affiliations：
  
  1.The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou (510006), China
  2.Department of Neurology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou (510120), China
  3.Department of Acupuncture and Moxibustion, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan (430061), China
  4.Department of Neurology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning (530011), China
  5.Department of Neurology, Guangdong Second Traditional Chinese Medicine Hospital, Guangzhou (510095), China
  6.Department of Traditional Chinese Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai (200062), China
  7.Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing (100053), China
  8.Department of Traditional Chinese Medicine, Xiamen Hospital of Traditional Chinese Medicine, Xiamen (361001), China
  9.Department of Acupuncture and Moxibustion, The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha (410005), China
  10.Department of Neurology, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang (110032), China
  11.School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan (430030), China
  12.Youcare Pharmaceutical Group Dingcheng Branch, Beijing (100176), China
- Author bio：
  
  Correspondence to: Prof. CAI Ye-feng, E-mail:caiyefeng@126.com
- Funds：
- DOI：10.1007/s11655-020-3094-7
  CLC：
- Published：01 June 2020，
  
  Published Online：02 May 2020，
  
  Accepted：01 April 2020
Scan for full text
Ming-zhe HU, Zi-yi ZHOU, Zhong-yu ZHOU, et al. Effect and Safety of Hydroxysafflor Yellow A for Injection in Patients with Acute Ischemic Stroke of Blood Stasis Syndrome: A Phase Ⅱ, Multicenter, Randomized, Double-Blind, Multiple-Dose, Active-Controlled Clinical Trial. [J]. Chinese Journal of Integrative Medicine 26(6):420-427(2020)
DOI：

Ming-zhe HU, Zi-yi ZHOU, Zhong-yu ZHOU, et al. Effect and Safety of Hydroxysafflor Yellow A for Injection in Patients with Acute Ischemic Stroke of Blood Stasis Syndrome: A Phase Ⅱ, Multicenter, Randomized, Double-Blind, Multiple-Dose, Active-Controlled Clinical Trial. [J]. Chinese Journal of Integrative Medicine 26(6):420-427(2020) DOI： 10.1007/s11655-020-3094-7.

摘要

Abstract

Objective:

To assess the effect and safety of Hydroxysafflor Yellow A for Injection (HSYAI) in treating patients with acute ischemic stroke (AIS) and blood stasis syndrome (BSS).

Methods:

A multicenter

randomized

double-blind

multiple-dose

active-controlled phase Ⅱ trial was conducted at 9 centers in China from July 2013 to September 2015. Patients with moderate or severe AIS and BSS were randomly assigned to low-

medium-

high-dose HSYAI groups (25

50 and 70 mg/d HSYAI by intravenous infusion

respectively)

and a control group (Dengzhan Xixin Injection (灯盏细辛注射液

DZXXI) 30 mL/d by intravenous infusion)

for 14 consecutive days. The primary outcome was the Modified Rankin Scale (mRS) score ≤1 at days 90 after treatment. The secondary outcomes included the National Institute of Health Stroke Scale (NIHSS) score ≤1

Barthel Index (BI) score ≥95

and BSS score reduced ≥30% from baseline at days 14

and 90 after treatment. The safety outcomes included any adverse events during 90 days after treatment.

Results:

Of the 266 patients included in the effectiveness analysis

65 and 68 cases were in the low-

medium-

and high-dose HSYAI and control groups

respectively. The proportions of patients in the medium- and high-dose HSYAI groups with mRS score ≤1 at days 90 after treatment were significantly larger than the control group (

0.05). The incidences of favorable outcomes of NIHSS and BI at days 90 after treatment as well as satisfactory improvement of BSS at days 30 and 60 after treatment in the medium- and high-dose HSYAI groups were all significantly higher than the control group (

0.05). No significant difference was reported among the 4 groups in any specific adverse events (

0.05).

Conclusions:

HSYAI was safe and well-tolerated at all doses for treating AIS patients with BSS. The medium (50 mg/d) or high dose (75 mg/d) might be the optimal dose for a phase Ⅲ trial. (Registration No. ChiCTR-2000029608)

关键词

Keywords

hydroxysafflor yellow Aacute ischemic strokerandomized controlled trialblood stasis syndromeChinese medicine

references

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Effect and Safety of Herbal Medicine Foot Baths in Patients with Diabetic Peripheral Neuropathy: A Multicenter Double-Blind Randomized Controlled Trial

Reyanning Mixture on Asymptomatic or Mild SARS-CoV-2 Infection in Children and Adolescents:A Randomized Controlled Trial

Efficacy of Biejiajian Pill on Intestinal Microbiota in Patients with Hepatitis B Cirrhosis/Liver Fibrosis:A Randomized Double-Blind Controlled Trial

Efficacy of Wen-Luo-Tong on Peripheral Neuropathy Induced by Chemotherapy or Target Therapy: A Randomized,Double-Blinded, Placebo-Controlled Trial

Related Author

No data

Related Institution

Department of Endocrinology, Guangdong Provincial Hospital of Chinese Medicine

Department of Endocrinology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

Guangdong Provincial Academy of Chinese Medical Sciences

Department of Endocrinology, The First Affiliated Hospital of Henan University of Chinese Medicine

Department of Endocrinology, Liuyang Hospital of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰